Breast Cancer Clinical Trial
Study of Cardiopulmonary Exercise Testing in Women Who Have HER2-Positive Breast Cancer With Mild Cardiotoxicity
The purpose of this study is to find out how much oxygen is used during a cardiopulmonary exercise test (CPET) in women who have mild cardiotoxicity after standard treatment for HER2-positive breast cancer, and to see whether the results of this test can be used to predict how well participants' heart and lungs will work if they continue to receive this kind of treatment.
Age ≥ 18 years
Diagnosed with a HER2-positive solid tumor (stage I-IV)
Left ventricular dysfunction prior to the start of HER2-targeted therapy, defined by a LVEF < 53% (or lower limit of normal), or diagnosed with mild cardiotoxicity associated with HER2-targeted therapy, defined by an absolute decrease in LVEF ≥ 10% from pre-treatment to < 53%
Planning to undergo treatment with HER2-targeted therapy (e.g. trastuzumab, pertuzumab, or ado-trastuzumab) for a minimum of 3 months (i.e. 4 cycles administered every 3 weeks).
Willing and able to comply with the requirements of the protocol
Symptomatic heart failure (New York Heart Association Class III or IV)
Subjects must not have any of the following absolute contraindications to cardiopulmonary exercise testing:
Acute myocardial infarction (within 30 days of any planned study procedures),
Uncontrolled arrhythmias causing symptoms or hemodynamic compromise,
Symptomatic severe aortic stenosis
Acute myocarditis or pericarditis
Acute pulmonary embolus or pulmonary infarction (within 3 months of any planned study procedures)
Thrombosis of lower extremities (within 3 months of any planned study procedures)
Suspected dissecting aneurysm
Room air desaturation at rest ≤ 85%
Acute noncardiopulmonary disorder that may affect exercise performance or be aggravated by exercise (i.e., infection, renal failure, thyrotoxicosis)
Mental impairment leading to inability to cooperate.
Enrollment onto any other interventional investigational study
Inability to provide informed consent
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.